hotspot -WSS

hotspot

author：fashion 2025-10-02 05:38:13 - browse：81

Illustration of a teal cancer cell. -- health coverage from STAT — Illustration of a teal cancer cell. Adobe

Sana Biotechnology, a startup that just a couple of years ago raised over $1 billion off a grand plan to create a portfolio of powerful medicines, said Tuesday it would lay off nearly a third of its employees and de-prioritize one of its most ambitious programs as it looks to save money.

The layoffs are Sana’s second round of cuts in less than a year. It laid off 15% of staff last November after axing another program.

Tuesday’s move pushed back a program focused on turning a patient’s own immune cells into cancer-killing assassins or curing blood disorders such as sickle cell with just an IV infusion. Known as in vivo reprogramming, it was originally the company’s central focus and would have amounted to a monumental breakthrough.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Humana cuts profit projections as Medicare Advantage costs soar

entertainment

WSS

3 hurdles to bringing medical devices to the U.S. market

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

New brain studies show LSD's effects on the brain in full color

Why we need to separate burnout from moral injury in health care

Elizabeth Holmes banned from government health programs

Weight bias in eating disorder treatment complicated by new weight loss drugs

Wikipedia

hotspot

knowledge

What does generative AI mean for health care? We asked experts

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Independent physicians launch a new lobbying group

Medicare details structure of new drug price negotiation program

Why doctors need education on FDA device approval process

As demand for Covid shots wanes, Moderna seeks its next success

The strategy behind pharma's lawsuits over drug pricing reform

Trump demands the U.S. pay no more for drugs than other countries … again

Donald Trump's relentless attacks on special counsel Jack Smith

focus

Do masks work? RCTs can't tell us

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Ask STAT: What do you want to know about ChatGPT in medicine?

Research misconduct: Proposed new rules face resistance

The tragedy of Johnson & Johnson’s Covid vaccine

Prior authorization will have to move faster under new Biden rule

entertainment

hotspot

entertainment

focus